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Objectives: It is estimated that 30–40% of adolescents with major depressive disorder
(MDD) do not receive full benefit from current antidepressant therapies. Repetitive tran-
scranial magnetic stimulation (rTMS) is a novel therapy approved by the US Food and
Drug Administration to treat adults with MDD. Research suggests rTMS is not associated
with adverse neurocognitive effects in adult populations; however, there is no documen-
tation of its neurocognitive effects in adolescents. This is a secondary post hoc analysis
of neurocognitive outcome in adolescents who were treated with open-label rTMS in two
separate studies.
Methods: Eighteen patients (mean age, 16.2±1.1 years; 11 females, 7 males) with MDD
who failed to adequately respond to at least one antidepressant agent were enrolled in
the study. Fourteen patients completed all 30 rTMS treatments (5 days/week, 120% of
motor threshold, 10 Hz, 3,000 stimulations per session) applied to the left dorsolateral pre-
frontal cortex. Depression was rated using the Children’s Depression Rating Scale-Revised.
Neurocognitive evaluation was performed at baseline and after completion of 30 rTMS
treatments with the Children’s Auditory Verbal Learning Test (CAVLT) and Delis–Kaplan
Executive Function System Trail Making Test.
Results: Over the course of 30 rTMS treatments, adolescents showed a substantial
decrease in depression severity. Commensurate with improvement in depressive symp-
toms was a statistically significant improvement in memory and delayed verbal recall. Other
learning and memory indices and executive function remained intact. Neither participants
nor their family members reported clinically meaningful changes in neurocognitive function.
Conclusion: These preliminary findings suggest rTMS does not adversely impact neu-
rocognitive functioning in adolescents and may provide subtle enhancement of verbal
memory as measured by the CAVLT. Further controlled investigations with larger sample
sizes and rigorous trial designs are warranted to confirm and extend these findings.
Keywords: adolescents, depression, neurocognition, memory, learning,TMS
INTRODUCTION
Repetitive transcranial magnetic stimulation (rTMS) is a novel
treatment approach for medication-resistant patients with major
depressive disorder (MDD). Repetitive TMS has been approved by
the US Food and Drug Administration for the treatment of adults
with MDD who fail to achieve satisfactory improvement from one
prior adequate antidepressant treatment trial. Although several
sham-controlled studies have indicated that rTMS is efficacious in
adults with MDD (1–4), there have been few studies in adolescents.
We recently reported results of an open-label pilot study that found
rTMS to be a potentially effective adjunctive therapy for ado-
lescents with treatment-resistant MDD (5). Adolescents showed
statistically significant improvement in the Children’s Depression
Rating Scale-Revised (CDRS-R) from baseline through the rTMS
treatment series (30 sessions) and at 6-month follow-up. A sec-
ond, recently completed replication trial in 10 adolescents revealed
similar findings for clinical improvement in treatment completers
(submitted). In both studies, assessments of cognitive functioning
were performed at baseline and treatment completion.
A number of studies have indicated that rTMS treatment for
MDD is not associated with adverse effects on neuropsycholog-
ical functions such as attention, learning, and memory (2, 3,
6–9), but these investigations have only included adults. Not only
have studies not shown any deterioration in neuropsychological
functioning from rTMS, but several investigations have shown
an improvement in neurocognitive function in adult patients
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with MDD. For example, in a sham-controlled study by Avery
et al. (1), adults with MDD showed considerably improved per-
formance on measures of attention, learning and memory, and
cognitive flexibility following 10 sessions of 10 Hz rTMS applied
to the left dorsolateral prefrontal cortex (L-DLPFC). Further-
more, two sham-controlled studies reported improvement in
verbal memory performance as a result of multiple sessions of
10 Hz rTMS treatment to the L-DLPFC in adults with MDD
(10, 11). Also, following multiple sessions of 10 Hz rTMS to the
L-DLPFC in depressed adults, Fitzgerald et al. (12) found that
there was significant improvement in neuropsychological func-
tion, including autobiographical memory; and Martis et al. (13)
reported improvement in working memory and executive func-
tion. Recently, Luber and Lisanby described a review of over 60
TMS studies that reported “significant improvements in speed
and accuracy in a variety of tasks involving perceptual, motor,
and executive processing” (14).
In the present study we evaluated the neurocognitive effects
of rTMS when used as an adjunctive treatment for adolescents
with treatment-resistant MDD. We hypothesized that adolescents
would demonstrate no difference in measures of memory, execu-
tive functioning, or auditory and visual learning tasks following a
robust course of left-sided, high-frequency rTMS.
MATERIALS AND METHODS
PARTICIPANTS
Participants were diagnostically assessed by a board-certified child
and adolescent psychiatrists (Paul E. Croarkin and Christopher A.
Wall). This included a comprehensive clinical evaluation and stan-
dardized diagnostic interview that utilized the Kiddie Schedule
for Affective Disorders and Schizophrenia for School-Age Chil-
dren – Present and Lifetime Version (K-SADS-PL) (15). At the
time of enrollment, all participants were receiving active antide-
pressant treatment for an MDD episode according to the Diag-
nostic and Statistical Manual of Mental Disorders, Fourth Edition,
Text Revision (DSM-IV-TR) (16). Clinically significant depres-
sive symptoms were defined by CDRS-R (17) total score of at
least 40 (t score >63). Participants included those with treat-
ment failure/non-response to at least one adequate antidepressant
trial [i.e., treated with stable selective serotonin reuptake inhibitor
(SSRI) dose regimen for at least 6 weeks as defined by a score
of ≥3 on the Antidepressant Treatment History Form] (18). All
participants continued treatment with a stable dose of their pre-
study antidepressant during the rTMS course. Participants in
psychotherapy were ineligible if they had changed therapists, type
of psychotherapy, or providers in the 4 weeks prior to rTMS ini-
tiation. Participants were allowed to continue previous sleep aids
such as melatonin, trazodone, or diphenhydramine during treat-
ment. Stimulants, antipsychotics, mood stabilizers, and tricyclic
antidepressants were not permitted during the active treatment
phase.
Patients with comorbid secondary diagnoses of dysthymia,
attention-deficit/hyperactivity disorder, or anxiety disorders were
eligible for enrollment. However, patients with schizophre-
nia, schizoaffective disorder, bipolar spectrum disorders, sub-
stance abuse or dependence, somatoform disorders, dissociative
disorders, post-traumatic stress disorder, obsessive-compulsive
disorder, eating disorders, mental retardation, or pervasive
developmental disorder/autism spectrum disorders were excluded
from participation. Medical exclusions included preexisting
seizure disorders or active neurologic conditions (e.g., brain
tumor, dyskinesias, or paralysis). The screening process included
a urine toxicology screen for drugs of abuse and a urine preg-
nancy test. All participants and treaters wore earplugs dur-
ing the sessions to minimize the risk of auditory threshold
changes.
STUDY OVERVIEW
Both trials were prospective, open, multicenter pilot trial of active
rTMS in adolescents with MDD confirmed by the K-SADS-PL.
Both studies received institutional review board approval and
were performed under United States Food and Drug Adminis-
tration Investigational Device Exemptions: trial #1 – G060269
and trial #2 – G110091. All patients provided written informed
assent, and parents provided written informed consent per institu-
tional review board-approved guidelines. Recruitment, outcomes,
and potential adverse effects were monitored by a Data and
Safety Monitoring Board comprised of clinicians with no direct
involvement in the study.
rTMS PROCEDURES
Identification of the treatment site and stimulus dosing were based
on previously defined techniques and guidelines noted in adult
rTMS trials (4, 19). In both trials, the motor cortex was identified,
using the rTMS machinery via a single pulse administered every
3–5 s, at the location that produced a localized contraction of the
contralateral abductor pollicis brevis muscle. Once this site was
defined, the resting motor threshold (MT) was determined using a
computer-assisted maximum likelihood threshold-hunting algo-
rithm (MT Assist, Neuronetics Inc., Malvern, PA, USA). Repeat
MT determinations occurred at least once every 10 treatments to
assess for possible changes that could produce safety issues due to
changes in cortical excitability.
In trial #1, the L-DLPFC treatment location was determined
by moving the treatment coil 5 cm anterior to the MT loca-
tion along a left superior oblique plane (20). In trial #2, the
L-DLPFC treatment location was determined via an MRI-based
neurolocalization technique. The identified treatment site was
then marked and spatial coordinates were recorded with a mechan-
ical coil positioning system to ensure reproducibility of the coil
placement.
In both trials, a total of 30 treatments were administered across
a range of 6–8 weeks. This range was chosen for potential varia-
tion in patient schedules related to school and family events. Thus,
each patient was offered a total of 40 treatment opportunities
in which to complete 30 treatments. Each treatment was titrated
to 120% of calculated MT, at a frequency of 10 Hz, with stimu-
lus train duration of 4 s and an inter-train interval of 26 s, for a
total of 3,000 stimulations per treatment session. In trial #1, rTMS
was delivered using the Neuronetics Model 2100 Therapy System;
in trial #2 treatments were delivered using the NeuroStar System
(Neuronetics, Inc., Malvern, PA, USA).
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NEUROCOGNITIVE ASSESSMENTS
Neurocognitive testing was administered by trained psychome-
trists at baseline and upon completion of the active rTMS treat-
ments. Testing was typically performed in the afternoon hours,
although not universally due to scheduling accommodations
related to subject school obligations, family work hours, and
clinician/psychometrist availability. A doctorate-level child psy-
chologist (Leslie A. Sim) analyzed the results. The neurocognitive
battery was tailored to assess a variety of neurocognitive domains
including psychomotor speed, simple attention, learning, mem-
ory, and executive function. Specifically, the battery included the
Children’s Auditory Verbal Learning Test-2 (CAVLT-2) (21) and
the Delis–Kaplan Executive Function System (D-KEFS) (22) Trail
Making Test.
The CAVLT-2 (21) is a measure designed to quantify a child’s
(ages 6.6–17.11) verbal learning and memory abilities. The mea-
sure is comprised of a 16-item word list that is administered across
five trials, and the participant is asked to recall the words after each
trial. A different set of words is then presented and the participant
is asked to immediately recall the items from the new list (Inter-
ference Trial). Following the interference list, the participant is
instructed to recall as many items as possible from the original
list (immediate recall). Following a 15 min delay, the participant
is asked to recall the original list for a final time (delayed recall).
Finally, the participant is presented with a 32-item word list and
asked to recognize the 16 words from the original list (Recogni-
tion Trial). The CAVLT-2 yields multiple indices of learning and
memory, including immediate memory span, level of learning,
immediate recall, delayed recall, recognition accuracy, and total
intrusions.
The D-KEFS Trail Making Test is used to assess components
of cognitive flexibility on a visual-motor sequencing task (23).
It consists of five conditions: (a) Visual Scanning, (b) Num-
ber Sequencing, (c) Letter Sequencing, (d) Motor Speed, and
(e) Number-Letter Switching. The D-KEFS Trail Making Test
was selected to assess aspects of executive function, particularly
cognitive flexibility, as it is influenced by mood and anxiety
states. Importantly, the D-KEFS has been normed for the age
group of children in this trial and provides standardized scores
(24). Based on adequate reliability and validity of these tests
along with appropriate developmental normative data, these neu-
ropsychological measures (CAVLT-2 and D-KEFS TMT) were
thought to be developmentally appropriate tools to assess sub-
tle changes in cognitive function of adolescents receiving rTMS
treatments.
Safety and participant comfort were assessed and recorded
before and after each study visit with prompted opportunities to
report adverse events.
STATISTICAL ANALYSIS
The primary aim of this study was to assess whether adjunctive
rTMS is a safe and feasible treatment approach in adolescents.
This question was evaluated by neurocognitive assessments that
occurred at baseline and immediately following treatment number
30. Within patient changes from baseline to treatment completion
were examined with comparative statistics.
Neurocognitive measurements obtained at baseline and imme-
diately following treatment were summarized using mean and
standard deviation (±SD). The paired t -test was used to assess
whether scores changed significantly from baseline to end of treat-
ment. For these analyses, two-tailed P-values of ≤0.05 were con-
sidered statistically significant. In addition to the primary analyses
which included all enrolled subjects, a subset analysis was per-
formed that was restricted to subjects who completed treatment.
All analyses were performed using SAS software, version 9.2 (SAS
Institute Inc., Cary, NC, USA).
RESULTS
Of the 18 adolescents enrolled in both trials, 14 adoles-
cents (5 males and 9 females; ages 13.9–17.8 years; mean age,
16.3± 1.1 years) completed the entire rTMS treatment course
(clinicaltrials.gov Identifier: NCT00587639). Fourteen out of 14
adolescents who completed the entire treatment course also com-
pleted neurocognitive testing at baseline and treatment com-
pletion. Subjectively, no reportable changes in memory, cogni-
tive functioning, or attention were noted by any of the par-
ticipating adolescents or their families. Objectively, subtle but
statistically significant improvement was observed in immedi-
ate memory and delayed recall as measured by the CAVLT
when measured in all study participants (Table 1; Figure 1) and
participants who completed all 30 rTMS sessions of the treat-
ment protocol (Table 2; Figure 2). All other CAVLT indices
of learning and memory (interference, immediate recall, or
level of learning) remained stable over the course of treatment
(Table 1).
No significant changes were noted on the D-KEFS Trail Making
Test indices from baseline to treatment completion for either the all
participant group (Table 3; Figure 3) or the treatment completers
only group (Table 4; Figure 4).
DISCUSSION
To our knowledge, this is the first report on neurocognitive
outcomes within a clinical trial of rTMS in depressed adoles-
cents. The neurocognitive safety findings of this case series of
high-frequency rTMS in treatment-resistant depressed adoles-
cents are consistent with previously reported findings in clin-
ical trials of rTMS in adults with psychiatric illness. Previ-
ous adult trials have frequently included cognitive assessments
that demonstrated rTMS to have no adverse effects on cogni-
tive functions (2, 3, 6–9, 25). Interestingly, a number of these
clinical trials in adults have shown time-limited improvements
in various aspects of cognitive function, mainly in attention,
concentration, working memory, and processing speed (10–
13). Similarly, modest improvements in attention, and verbal
and learning and memory were observed in this cohort of
adolescents.
LIMITATIONS
Clearly, these findings must be interpreted with caution due to
the small total number of participants and the lack of a control
group. However, if there was a distinct pattern of clinically and
psychometrically meaningful adverse cognitive effects – as could
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Table 1 | Children’s AuditoryVerbal LearningTask (CAVLT) results (all participants).
CAVLT subscales N Score Change from baseline Change P -value Cohen’s d
Mean Mean (SD) (95% CI)
Immediate Memory Scale BL 18 98.6 – – – –
PT 18 113.1 14.5 (12.0) (8.5, 20.5) <0.0001 0.81
Level of learning BL 18 98.4 – – – –
PT 18 106.2 7.7 (17.7) ( −1.1, 16.5) 0.0814 0.37
Interference BL 18 104.4 – – – –
PT 18 109.2 4.7 (13.1) (−1.8, 11.2) 0.1434 0.30
Immediate recall BL 18 98.5 – – – –
PT 18 100.2 1.7 (11.9) (−4.2, 7.6) 0.5596 0.08
Delayed recall BL 18 94.7 – –
PT 18 102.3 7.6 (13.8) (0.7, 14.5) 0.0319 0.33
BL, baseline; PT, post-treatment.
FIGURE 1 | CAVLT results (all participants).
be found in a robust course of electroconvulsive therapy – we
would expect to see these findings even in this small group of
participants. It is reassuring to note that none of the participants
or their family members described any impairments (or marked
improvements) in learning, memory, or other untoward cognitive
effects.
CONCLUSION
Collectively, the findings of this study combined with our prior
clinical findings suggest that rTMS may be a safe, feasible, and
potentially efficacious adjunctive therapy for adolescents with
MDD given the lack of negative changes in cognitive function-
ing and reduced overall side-effect burden (4, 5). Future studies of
rTMS in adolescents will need to monitor for cognitive changes,
which would benefit from the use of a comprehensive, standard-
ized, and validated neurocognitive battery that will be sensitive
to cognitive changes, particularly in those cognitive domains
essential for continued academic maturation and instrumental
activities of daily living. Such a neurocognitive battery should
assess domains of intellectual ability, processing speed, attention,
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Table 2 | Children’s AuditoryVerbal LearningTask (CAVLT) results (treatment completers).
CAVLT subscales N Score Change from baseline Change P -value Cohen’s d
Mean Mean (SD) (95% CI)
Immediate Memory Scale BL 14 95.6 – – – –
PT 14 109.4 13.8 (12.6) (6.5, 21.1) 0.0013 0.77
Level of learning BL 14 99.4 – – – –
PT 14 105.1 5.7 (18.8) (−5.2, 16.6) 0.2764 0.25
Interference BL 14 101.1 – – – –
PT 14 106.1 5.0 (13.2) (−2.6, 12.6) 0.1786 0.31
Immediate recall BL 14 97.3 – – – –
PT 14 99.9 2.6 (13.3) (−5.1, 10.3) 0.4707 0.11
Delayed recall BL 14 94.9 – –
PT 14 100.9 6.0 (14.1) (−2.1, 14.1) 0.1353 0.24
BL, baseline; PT, post-treatment.
FIGURE 2 | CAVLT results (completers only).
Table 3 | Delis–Kaplan Executive Function System (D-KEFS)Trail MakingTest results (all participants).
D-KEFS subscales N Score Change from baseline Change P -value Cohen’s d
Mean Mean (SD) (95% CI)
Number sequencing BL 18 10.1 – – – –
PT 18 11.1 1.1 (3.2) (−0.5, 2.7) 0.1735 0.38
Letter sequencing BL 18 10.3 – – – –
PT 18 11.3 1.0 (2.9) (−0.4, 2.4) 0.1604 0.42
Composite score BL 18 10.7 – – – –
PT 18 11.8 1.1 (2.9) (−0.4, 2.6) 0.1259 0.43
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FIGURE 3 | D-KEFS results (all participants).
Table 4 | Delis–Kaplan Executive Function System (D-KEFS)Trail MakingTest results (treatment completers).
D-KEFS subscales N Score Change from baseline Change P -value Cohen’s d
Mean Mean (SD) (95% CI)
Number Sequencing BL 14 10.3 – – – –
PT 14 11.1 0.9 (3.6) (−1.2, 3.0) 0.3854 0.28
Letter sequencing BL 14 10.9 – – – –
PT 14 11.6 0.7 (2.7) (−0.9, 2.3) 0.3405 0.31
Composite score BL 14 11.2 – – – –
PT 14 12.0 0.8 (3.1) (−1.0, 2.6) 0.3629 0.30
FIGURE 4 | D-KEFS results (completers only).
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learning and memory, working memory, and executive function.
Indeed, Semkovska and McLoughlin recommended the develop-
ment of standardized and validated tools to measure the ability
to recall autobiographical events in patients with depression (26).
Such a measure would be of particular value in the adolescent
population.
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